-
The competition in the pharmaceutical industry has intensified, and pharmaceutical companies are accelerating the divestment of some businesses
Time of Update: 2022-05-16
On April 1, the multinational pharmaceutical company Daiichi Sankyo also announced that it will sign an equity transfer agreement with Chongqing Yaoyou Pharmaceutical, a subsidiary of Fosun Pharma, to transfer the production and sales rights of Colibidone tablets and Colibiduo injections in mainland China.
-
New trend of multinational pharmaceutical companies in China?
Time of Update: 2022-05-16
On April 27, AstraZeneca China told Cyberlane that the cooperation with Chengdu High-tech Zone to build a traditional Chinese medicine innovation industry base will help AstraZeneca focus on the modernization and innovative development of traditional Chinese medicine, and promote the exchange of international experience .
-
Domestic and foreign pharmaceutical companies are rushing in, and the $100 billion market has become a "sweet pastry"
Time of Update: 2022-05-16
However, in recent years, with the increasing attention of rare diseases in the industry and the continuous introduction of a series of favorable policies at home and abroad to encourage pharmaceutical companies to make drugs for rare diseases, the market is expanding .
-
Nearly 80% of in vitro diagnostic companies reported good results, and 11 companies including Rejing Biotech increased by over 100% year-on-year
Time of Update: 2022-05-16
Among them, nearly 80% of the in vitro diagnostic companies reported good performance, and 11 companies saw a year-on-year increase of more than 100%, including Jimin Medical, Rejing Bio, Xinkaiyuan, Jiu'an Medical, Mingde Bio, Wantai Bio, and Oriental Bio .
-
Henan announced the sales of the top 100 pharmaceutical companies in the first quarter: Hengrui, Qilu, Chia Tai Tianqing...
Time of Update: 2022-05-16
01 The ranking has changed, and domestic top pharmaceutical companies have an advantage01 The ranking has changed, and domestic top pharmaceutical companies have an advantageOn April 26, the Henan Provincial Public Resource Trading Center issued the "Notice on Publicizing the Province's Online Drug Transactions in the First Quarter of 2022" (hereinafter referred to as the "Notice") .
-
In 2022, the expansion of large chain pharmacies is still accelerating!
Time of Update: 2022-05-16
At present, the total number of stores of chain pharmacies such as Sinopharm Accord, Yifeng Pharmacy, and Jointown is increasing year by year through self-operation, franchise, mergers and acquisitions, etc.
-
A large number of medical equipment sampling failed!
Time of Update: 2022-05-16
Recently, the State Food and Drug Administration's newly issued notice on the results of national medical device supervision and sampling shows that the State Food and Drug Administration recently organized a product quality supervision and sampling inspection of 5 varieties including intervertebral fusion devices and semiconductor laser treatment machines, a total of 12 batches.
-
Sinopharm, Kexing Omicron variant new crown vaccine approved for clinical use in China
Time of Update: 2022-05-16
On April 26, 2022, Sinopharm Group China Biotechnology and SINOVAC Kexing developed the new coronavirus inactivated vaccine based on the Omicron variant strain (Omicron), respectively, and obtained clinical approval from the State Drug Administration on the same day .
-
The State Food and Drug Administration released the catalogue of the fifty-third batch of generic drug reference preparations
Time of Update: 2022-05-16
On April 24, the State Food and Drug Administration issued an announcement stating that, after review and confirmation by the Expert Committee on Consistency Evaluation of Generic Drug Quality and Efficacy, the catalogue of generic drug reference preparations (the fifty-third batch) is now released .
-
Good news this month!
Time of Update: 2022-05-16
Junshi Bio: Anti-CD112R Monoclonal Antibody Approved in the United States On April 3, Junshi Bio announced that its self-developed anti-CD112R monoclonal antibody injection (project code: TAB009/JS009) is used in clinical trials for the treatment of advanced solid tumors The trial application has been approved by the US FDA .
-
Industry: The market of traditional Chinese medicine formula granules will accelerate the expansion, approaching the 100 billion yuan mark
Time of Update: 2022-05-16
In order to promote the development of traditional Chinese medicine formula granules, on December 30, 2021, the two departments jointly issued the "Guiding Opinions on Medical Insurance Supporting the Inheritance and Innovation of Traditional Chinese Medicine", which encourages the inclusion of traditional Chinese medicine formula granules purchased by public medical institutions into the provincial centralized pharmaceutical procurement platform.
-
A large proportion of innovative pharmaceutical companies broke, and one company achieved "U-picking"
Time of Update: 2022-05-16
. Among them, China Cell stated that during the reporting period, the company's self-developed product Ancaine (SCT800, recombinant human coagulation factor VIII) was approved for listing in July 2021, and began to generate sales revenue continuously.
-
This pharmaceutical company has another new ADC drug for clinical application!
Time of Update: 2022-05-16
Specifically, BAT8009, which was also approved for clinical use in April, is a B7H3-targeting antibody-drug conjugate (ADC) developed by Bio-Tech, which is intended to be developed for the treatment of solid tumors .
-
In 4 months, a large number of presidents and vice presidents of pharmaceutical companies have resigned or replaced!
Time of Update: 2022-05-16
It is worth mentioning that on January 6, Buchang Pharmaceutical announced that the board of directors received a written resignation report submitted by the vice president of the company, Mr.
-
In 2022, the development of traditional Chinese medicine industry will face great challenges!
Time of Update: 2022-05-16
On April 24, in order to implement the deployment of the in-depth special rectification action for drug safety, the State Food and Drug Administration held a promotion meeting for the special rectification of traditional Chinese medicines .
-
The process of centralized procurement of proprietary Chinese medicines is accelerating, and the transformation and upgrading of enterprises is at the right time
Time of Update: 2022-05-16
In addition, the centralized procurement of Chinese patent medicines of the 6-province alliance in Guangdong also announced the results of the proposed selection/alternative recently.
. In addition, it is worth mentioning that many companies are currently increasing investment in research and development to accelerate the innovation of traditional Chinese medicine .
-
The EU's first migraine drug with both curative/preventive action!
Time of Update: 2022-05-16
CompilationFan DongdongRecently, Vydura (rimegepant), a calcitonin gene-related peptide (CGRP) receptor antagonist developed by Pfizer and Biohaven, received marketing authorization from the European Commission (EC) for the treatment of acute migraine with or without aura, and Prevention of adult-onset migraine headaches with at least 4 attacks per month .
-
A group of executives of pharmaceutical companies are frequently "running away"!
Time of Update: 2022-05-16
Not long ago, AstraZeneca also issued an internal announcement: Lu Yanbin, the current deputy director of the Strategic Project Management Office, will leave the company to seek external development opportunities due to personal reasons .
-
Amgen Announces New Data from Two OLE Studies of PCSK9 Inhibitor Repatha in ASCVD
Time of Update: 2022-05-16
CompilenewbornRecently, Amgen announced the top-line results of two open-label extension (OLE) studies of the PCSK9 inhibitor lipid-lowering drug Repatha (Repatha, generic name: evolocumab) Phase 3 FOURIER cardiovascular outcomes trial .
-
BeiGene's CD3/CD19 Dual Antibody Belintoumumab New Indication Approved
Time of Update: 2022-05-14
Article source: Medical Cube InfoAuthor: infoOn April 29, BeiGene's new indication of belintoumumab for injection submitted by BeiGene was approved by the State Food and Drug Administration for the treatment of relapsed or refractory precursor B-cell acute lymphoblastic leukemia in adults and children .
